After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Xeris Biopharma Holdings Inc. (XERS) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $2.31. The Xeris Biopharma Holdings Inc. has recorded 17,265 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $2.31 and fluctuated between $2.4100 as its day high and $2.2900 as its day low. The current market capitalization of Xeris Biopharma Holdings Inc. is $300.30M. A total of 1.3 million shares were traded on the day, compared to an average of 1.19M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, XERS has seen 1 BUY and 0 SELL insider trades, representing the acquisition of 85,000 and the disposition of 0 shares. Over the last 12 months, there were 16 BUYs and 0 SELLs from insiders. Insiders purchased 3,160,000 shares during that period but sold 0.
In the most recent transaction, Edick Paul R bought 20,000 shares of XERS for 1.45 per share on Dec 13. After the transaction, the insider now owns 1,528,064 company shares. In a previous transaction on May 12, Edick Paul R bought 100,000 shares at 1.40 per share. XERS shares that insider owns now total 1,508,064.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for XERS in the last 3 months, the mean price target is $5.00 with high estimates of $6.00 and low estimates of $4.00. In terms of 52-week highs and lows, XERS has a high of $2.53 and a low of $0.97.
As of this writing, XERS has an earnings estimate of $-0.17 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $-0.16 per share and a lower estimate of $-0.18.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. XERS’s latest balance sheet shows that the firm has $102.43M in Cash & Short Term Investments as of fiscal 2021. There were $88.07M in debt and $79.04M in liabilities at the time. Its Book Value Per Share was $0.33, while its Total Shareholder’s Equity was $95.23M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XERS is Buy with a score of 5.00. A total of 4 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.
